Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab

JAMA Pediatr. 2016 Feb;170(2):174-6. doi: 10.1001/jamapediatrics.2015.3235.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Humans
  • Infant
  • Palivizumab / administration & dosage*
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Viruses / immunology*

Substances

  • Antiviral Agents
  • Palivizumab